Skip to main content
PEPTARA LABS
Get Started

Mk-677

MK-677 (Ibutamoren): Oral GH Secretagogue

Published by · Updated · How we research and check our pages

The short answer

MK-677, also called ibutamoren, is an orally active ghrelin-mimetic growth hormone (GH) secretagogue. It is taken by mouth, not injected.

This page is general educational information, research-use framing only, not medical advice. Any decision about a research compound belongs with a qualified clinician.

What is MK-677 (ibutamoren)?

MK-677, known as ibutamoren, is an orally active compound that mimics ghrelin to signal the pituitary gland to release more growth hormone.

In the main human trial, oral MK-677 raised both GH and IGF-1 in healthy older adults over 12 months (Nass et al., 2008). Because it acts like ghrelin at the growth hormone secretagogue receptor, it is grouped with GH secretagogues rather than with GH itself. It does not add outside GH; it prompts the body to release more of its own.

How does MK-677 work in the body?

It binds the growth hormone secretagogue receptor, the same target ghrelin uses, prompting the pituitary to release GH in a pattern that tracks the body's own pulses.

This pulse-preserving action is part of why researchers studied it as an oral compound. Over a year in the trial, GH and IGF-1 stayed raised (Nass et al., 2008). GH then drives production of IGF-1, mostly in the liver, and IGF-1 carries out many of GH's downstream effects on tissue.

Is MK-677 a peptide, and why is it a pill instead of an injection?

Ibutamoren is a small molecule rather than a peptide, so it survives stomach acid and is absorbed when swallowed, which is why it does not need to be injected.

Many peptide GH secretagogues, such as ipamorelin, are injected because digestion would break them apart. MK-677 is often listed next to those peptides because it hits the same receptor, but its chemistry is different. The 12-month trial gave it by mouth (Nass et al., 2008). For background on the wider category, see what are peptides.

What has research tested for MK-677?

The main human trial gave healthy older adults one fixed oral amount or placebo for 12 months (Nass et al., 2008). This page reports the design and the findings and leaves the amount out: one study group is not advice for a reader.

The ranges below reflect what published studies and commonly studied research protocols report. This is educational, not a prescription or a personal recommendation.

SourcePopulationRouteDuration
Nass et al., 2008 (Annals of Internal Medicine)Healthy older adultsOral12 months

That 12-month trial by Nass et al. (2008), cited throughout this page, is the strongest human evidence on MK-677. Figures passed around elsewhere are not supported by it. Any personal decision belongs with a qualified clinician.

What is the half-life of MK-677?

A specific plasma half-life is not established in the sources cited here; what the trial confirms is that GH and IGF-1 stayed higher than placebo for the full 12 months (Nass et al., 2008).

IGF-1 that stays up across the trial points to a long duration of action. This page will not state an hour figure it cannot cite.

PropertyWhat the cited trial shows
RouteOral
Effect on GH and IGF-1Raised and sustained over 12 months (Nass et al., 2008)
Stated plasma half-lifeNot reported in the sources cited here

What did research find MK-677 does to body composition?

Over 12 months, MK-677 increased fat-free mass by about 1.1 kg in healthy older adults (Nass et al., 2008).

Fat-free mass measures lean tissue, which includes body water, so part of a measured gain can reflect fluid rather than contractile muscle. The trial's headline body-composition result was that roughly 1.1 kg lean-mass rise over a year (Nass et al., 2008). For how GH-axis compounds are studied for muscle more broadly, see peptides for muscle growth.

What are the reported side effects of MK-677?

The best-documented signal is metabolic: fasting blood glucose rose and insulin sensitivity fell over 12 months compared with placebo (Nass et al., 2008).

Because MK-677 raises GH and IGF-1, and GH can push blood sugar upward, the glucose finding fits its mechanism. Human safety data stay limited overall, and this page reports only what the cited trial documented. Anyone weighing these signals should work with a qualified clinician, especially with any history of blood-sugar problems.

How does MK-677 compare to ipamorelin and CJC-1295?

MK-677 is an oral small-molecule ghrelin mimetic, ipamorelin is an injectable selective GH secretagogue (Raun et al., 1998), and CJC-1295 is an injectable GHRH analog that sustained GH and IGF-1 (Teichman et al., 2006).

CompoundClassRouteCited finding
MK-677 (ibutamoren)Ghrelin-mimetic GH secretagogue (small molecule)Oral+1.1 kg fat-free mass over 12 months; higher fasting glucose, lower insulin sensitivity (Nass et al., 2008)
IpamorelinSelective GH secretagogue (peptide)InjectableSelective GH release with little effect on other hormones (Raun et al., 1998)
CJC-1295GHRH analog (peptide)InjectableSustained GH and IGF-1 (Teichman et al., 2006)

The practical split is route and target. MK-677 works orally at the ghrelin receptor. Ipamorelin also hits the ghrelin/GH secretagogue receptor but is a peptide given by injection, and it was characterized as highly selective for GH release (Raun et al., 1998). CJC-1295 uses a different door, the GHRH receptor, and was shown to sustain GH and IGF-1 (Teichman et al., 2006). Compare the injectable option on the ipamorelin page.

Is MK-677 sold as a medicine or supplement?

No. PeptaraLabs supplies MK-677 for laboratory and research use only; it is not a dietary supplement or an approved medicine.

Nothing here is medical advice, and nothing here promises a result. The research described comes from published trials in defined populations and may not apply to any individual.

Mk-677: FAQ

Is MK-677 the same as ibutamoren?

Yes. Ibutamoren is the common name for MK-677. Both refer to the same compound.

Is MK-677 a SARM?

No. It is a growth hormone secretagogue that acts at the ghrelin receptor, not a selective androgen receptor modulator. It works through the GH and IGF-1 axis (Nass et al., 2008).

Does MK-677 have to be injected?

No. It is orally active, and the year-long human trial gave it by mouth (Nass et al., 2008).

Does MK-677 raise blood sugar?

In the 12-month trial, fasting glucose rose and insulin sensitivity fell compared with placebo (Nass et al., 2008). Discuss this with a clinician if blood sugar is a concern.

What did the MK-677 trial report for lean mass?

The cited trial reported about a 1.1 kg gain in fat-free mass over 12 months in older adults (Nass et al., 2008). Fat-free mass is lean tissue, not a direct measure of strength, and results in other groups are not established here.

How fast does MK-677 work?

The cited trial measured change over 12 months and does not set a timeline for any individual (Nass et al., 2008). Response varies from person to person.

Is MK-677 safe?

Human safety data are limited. The clearest documented signal is metabolic: higher fasting glucose and lower insulin sensitivity (Nass et al., 2008). A qualified clinician should guide any personal decision.

References

  1. Nass R, Pezzoli SS, Oliveri MC, et al. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized, controlled trial. Ann Intern Med. 2008;149(9):601-611. doi:10.7326/0003-4819-149-9-200811040-00003. PMID: 18981485.
  2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. doi:10.1530/eje.0.1390552. PMID: 9849822.
  3. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PMID: 16352683.

Sourcing research-grade peptides?

Talk to the Peptara Labs team about purity, third-party certificates of analysis, and cold-chain shipping.

General educational information only, research-use framing, not medical advice. Confirm the current status where you live and consult a qualified professional before acting.

Chat with us